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Pulmonary aspergillosis encompasses a heterogeneous group of mycoses that result from either
colonisation or pathogenic damage of lung tissue by Aspergillus fungi. These clinical entities
range from relatively benign saprophytic hypersensitivity associated with fungal inhabitation
to life threatening invasive disease. The diagnosis of pulmonary disorders related to Aspergillus
is on the increase and it is more important than ever those both general and respiratory physi-
cians have a good understanding of these disorders. This paper reviews the contemporary under-
standing of the clinical, radiographic and histopathological aspects of pulmonary aspergillosis.
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several hundred species.
Only a minority are pathogenic to humans. Overall,
Aspergillus fumigatus is responsible for 80e90% of cases of
pulmonary aspergillosis.1 Fungal transmission results from
the inhalation of tiny airborne conidia which are small
enough to reach small peripheral airways. The sinuses and
skin provide other potential portals of entry into the body;
once breached, haematogenous dissemination places or-
gans such as the central nervous and cardiovascular system
at particular risk of infection.
In general, the severity of Aspergillus pulmonary disease
is directly related to the prevailing fungal burden (influ-
enced by the balance between integrity of host immunity
against the virulence of the fungus), the presence and na-
ture of existing lung disease and abnormal bronchial
defence mechanisms. The incidence of pulmonary asper-
gillosis has increased in recent years for a number of reasons
including an increased number of susceptible individuals
such as organ transplant recipients, a heightened clinical
awareness of the disease and improved methods for fungal
detection and disease characterization.1e4 In general, risk
factors for developing pulmonary aspergillosis can be
divided into: (1) evidence of suppressed immunity (including
infection with the human immunodeficiency virus, bone
marrow and solid organ transplantation, systemic anti-
biological therapies, prolonged corticosteroid use, poorly
controlled diabetes mellitus and chronic renal failure), (2)
presence of structural lung disease (cystic fibrosis,
sarcoidosis, chronic obstructive pulmonary disease) and (3)
factors that may promote fungal colonisation (wider use of
antimicrobials).1,4,5 The rising incidence of pulmonary
aspergillosis coupled with a multitude of disease suscepti-
bility factors means that such cases may increasingly be
encountered in outpatient clinics, medical admission de-
partments and the intensive care unit.
Disease manifestations
A. fumigatus is clinically the most important Aspergillus
species and its manifestations are diverse and sometimes
coincident. Traditionally, Aspergillus related pulmonary
disease has been divided into: Aspergillus rhinosinusitis,
trachoebronchitis, saprophytic aspergilloma, allergic bron-
chopulmonary aspergillosis (ABPA), chronic pulmonary
aspergillosis and invasive aspergillosis. Although these dis-
ease entities appear distinct, airway and parenchymal
manifestations of aspergillosis can occasionally co-exist in
the same individual.Airway-centred Aspergillus diseases
Aspergillus rhinosinusitis
The frequency of Aspergillus nasal and sinus disease in the
immune-competent host appears to have increased in
recent years, the reasons for which are not entirely
clear.6,7 Aspergillus can produce allergic (hypersensitivity)
and invasive rhinosinusitis as well as the formation of sinus
and parasinus fungal balls that may be mistaken for gran-
ulomatous or even malignant disease. Localized allergic
Aspergillus sinusitis often affects adolescents or young
adults with atopy and/or nasal polyposis; production of
eosinophil-rich ‘peanut butter’-like inspissated material is
a frequent complaint and may lead to sinus obstruction.8,9
Serum total IgE levels are typically elevated and Asper-
gillus may be cultured from biopsied nasal tissue.10 Positive
in vivo (skin testing) and in vitro (Aspergillus-specific IgE/
RAST) responses may also help support the diagnosis of
Aspergillus rhinosinusitis.11 The former may be more sen-
sitive than RAST testing in addition to being able to
demonstrate delayed cutaneous responses that measure-
ment of circulating IgE does not identify. Aspergillus-spe-
cific precipitins, typically IgG, may also be elevated in some
cases of allergic Aspergillus sinusitis. However, elevation of
these antibodies, like elevated total IgE, is not required to
prove a diagnosis of allergic Aspergillus sinusitis.12 Many
patients with Aspergillus sinusitis are also clinically and
immunologically sensitive to other fungi.
Computed tomography (CT) or magnetic resonance im-
aging (MRI) may demonstrate obliterated sinuses with hypo-
attenuated mucosae and focal areas of enhancing material
within the opacified spaces13 Apart from Aspergillus, other
dematiaceous fungi including Bipolaris and Curvularia can
also cause allergic fungal rhinosinusitis.14 Treatment with
oral corticosteroids following surgical removal of obstruct-
ing nasal tissue is advocated in most patients but systemic
antifungal treatment has not been shown to be effective.8
The results of studies using topical anti-fungals are
awaited.
Acute fulminant angio-invasive rhinosinusitis due to A.
fumigatus is characterized by the presence of fungal hy-
phae within the nasal mucosa and invasion into adjacent
vascular and bony structures. Although a relatively rare
condition affecting predominantly immune-compromised
patients, it is associated with a mortality of up to 80%
even with surgical intervention and aggressive systemic
antifungal therapy.15 Chronic granulomatous invasive
sinusitis is a distinct form of sinonasal disease found in parts
Table 1 Diagnostic criteria of ABPA.
Criteria Essential for
ABPA diagnosis?
Asthma Yes
Total IgE >1000 ng/mL (417 kU/L) Yes
Elevated serum IgE and/or IgG to
A. fumigatus
Yes
Immediate cutaneous reactivity to
Aspergillus species or
A. fumigatus
Yes
Central bronchiectasis
(inner two-thirds
of axial lung parenchyma)
Yes to diagnose
ABPA-central
bronchiectasis
If first four criteria
have been met,
diagnosis is ABPA
seropositive
(ABPA-s)
Infiltrates seen on chest radiograph No
Peripheral eosinophilia > 500 mm3 No
Precipitating antibodies to
A. fumigatus
No
Adapted from Greenberger, P. A. 2002. Allergic bronchopulmo-
nary aspergillosis. J Allergy Clin Immunol. 110(5): 685e92 (31).
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A. flavus in immune-competent individuals.13
Aspergillus tracheobronchitis
Before the term Aspergillus tracheobronchitis was adopted
in 1926, a number of reports had already documented
proximal large airway infection by Aspergillus fungi.16,17
Three different presentations of Aspergillus tracheo-
bronchitis were proposed in 1995, based partly on gross
morphology: obstructive, ulcerative and pseudomem-
branous.18 In practice, these different forms may co-exist.
In addition, Aspergillus tracheobronchitis may be coexis-
tent with other forms of Aspergillus-related pulmonary
disease. For example, pseudomembrane formation and
subsequent tissue destruction has also been associated with
invasive aspergillosis involving the distal lung parenchyma.
Neutropenia and systemic immunosuppression are major
risk factors for developing invasive Aspergillus tracheo-
bronchitis and account for its increasing frequency among
lung transplant recipients and patients with chronic auto-
immunediseases, acquired immune deficiency syndrome
(AIDS) and malignancy.19e23 Symptoms may be non-specific
and include cough in the majority, exertional dyspnoea,
blood-stained sputum, night sweats, fever and wheeze
which may be asymmetric.23,24 Radiographic findings
include endo-bronchial soft tissue thickening, obstruction
and tracheobronchial stenosis leading to segmental or
subsegmental lobar collapse.23 Bronchoscopic examination
and mucosal biopsy is essential for accurate diagnosis.
Macroscopic findings include luminal obstruction, mucosal
ulceration and exudative pseudomembranes adherent to
the underlying mucosa21 while microscopic demonstration
of fungal elements is both sensitive and specific for
Aspergillus tracheobronchitis and allows a confident diag-
nosis to be made.25
Administration of first-line systemic antifungal agents,
particularly voriconazole is recommended by the Infectious
Diseases Society of America (IDSA).1 In lung transplant re-
cipients, early detection of ulcerative Aspergillus trache-
obronchitis at surveillance bronchoscopy is associated with
a more favourable prognosis than the obstructive or pseu-
domembranous forms.23,25
Parenchymal pulmonary aspergillosis
Allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) was first
described by Hinson and colleagues in their 1952 report of
three patients with fever, wheezing, mucus production,
peripheral eosinophilia, pulmonary infiltrates and sputum
that cultured A. fumigatus.26 ABPA is a state of hypersen-
sitivity to highly antigenic A. fumigatus in atopic immune-
competent individuals whose airways are colonised by the
fungus. Although previously thought to affect only 1e2% of
asthmatics, a recent meta-analysis reported an ABPA
prevalence of 12.9% amongst patients attending asthma
clinics.27 Identification of Aspergillus in these individuals is
important as fungal sensitisation can increase the severity
of the underlying asthma.28 The prevalence of ABPA hasbeen estimated at between 2 and 15% in patients with
cystic fibrosis (CF).29,30
The hallmark immune abnormality in ABPA is that of an
aberrant T-helper cell type 2 (Th2) effector response to
Aspergillus spores which is mediated by IgE and IgG.31,32
Immuno-genetic characterization of ABPA has also dis-
closed human leukocyte antigen (HLA) associations as well
as a predisposition to aberrant CD4þ Th2 cytokine induc-
tion.33 In the immediate bronchial environment, the
release of such pro-inflammatory cytokines promotes both
type I and type III immune responses.34 The resulting
cellular inflammation is in turn exacerbated by repeated
exposure to Aspergillus antigens. Abnormal muco-ciliary
clearance in the bronchi may also play a role in the path-
ogenesis of ABPA.31
The diagnostic criteria for ABPA, initially proposed by
Rosenberg and colleagues, have undergone multiple re-
visions over the past 30 years resulting in the current
clinico-radiologic-pathologic approach shown in Table 1.35
The presence of five criteria is needed to secure a diag-
nosis of ABPA (Table 1); additional characteristics may
strengthen the diagnosis but their absence does not refute
it.36 In the minority of patients without central bronchiec-
tasis, the term ABPA-s has been used to denote seropositive
ABPA.37 This acknowledgement emphasizes the need for
clinical vigilance in identifying ABPA to avoid unnecessarily
delaying its diagnosis. ABPA-s has also been associated with
a milder disease course.38 The diagnosis of ABPA in the CF
population differs in some respects, according to criteria
agreed at the 2001 Cystic Fibrosis Foundation conference.39
Distinguishing lone asthma from asthma associated with
ABPA can be challenging.
Similarly, difficulties may also arise when differentiating
exacerbations of CF due to ABPA from ones that are not
1116 G. Tunnicliffe et al.Aspergillus-related.40 It is noteworthy that only a small
proportion of the increased total IgE levels measured in
ABPA are usually directed against Aspergillus.41 Although
total serum IgE levels may useful in monitoring disease,
they are subject to fluctuations and do not necessarily
predict clinical outcome.42
Many of the typical radiological features of ABPA are due
to the presence of dilated bronchi with thickened walls. On
plain chest radiographs, these abnormalities appear as ring
or linear opacities (representing widened bronchi seen en
face and in the coronal plane respectively) and have a pre-
dilection for the upper and central regions of the lungs. Signs
indicating endobronchial impaction by inspissated mucus
and fungal debris such as transient bronchocentric opacities,
lobar collapse and small peripheral lung nodules may also be
present.43 Fibrotic scarring, when evident, is more likely to
occur in the upper lung zones. CT features of ABPA include
central airway dilatation due to varicose or cystic bronchi-
ectasis, exudative bronchiolitis (tree-in-glove opacities) and
tubular ‘finger in glove’ shadows of dilated, impacted
bronchi.44 In a few cases, this is so marked as to produce the
‘hyperdense bronchial mucous plugging sign’ (Fig. 1).45
A clinical staging classification that takes into consider-
ation the typical relapsing-remitting nature of ABPA is also
in use.46 In reality, most patients do not progress predict-
ably through the different stages of disease although
recognition of the specific features of each stage aids
clinical phenotyping. Stages I (acute) and III (exacerbation)
represent the most symptomatic stages and are charac-
terized by, amongst others, marked elevations in serum IgE
and inflammatory radiographic opacities. At times of clin-
ical remission (stage II), these changes may abate and a
state of complete remission may become evident.31 Stage
IV describes a state of glucocorticoid-dependence to ach-
ieve either clinical or serological control while stage V
(‘end-stage’) is accompanied by established lung damage
such as fibrosis and/or extensive bronchiectasis. These
patients remain susceptible to clinical exacerbations.Figure 1 Coronal CT image of a patient with allergic bron-
chopulmonary aspergillosis (ABPA) demonstrating the hyper-
dense mucus sign. Arrows highlight high attenuation mucoid
impaction within abnormally dilated bronchi.Pharmacological management of ABPA is aimed at con-
trolling the host immunological response to Aspergillus anti-
gens and minimising the fungal antigen load within the
airways.46 In addition to corticosteroids as the mainstay of
immune-modulatory therapy, itraconazolehasemergedas the
antifungal drug of choice.47 Its short-term efficacy in
decreasing circulating IgE levels and inducing a steroid-sparing
effect has been demonstrated in two randomized controlled
trials.48 However, lasting benefit beyond the 16 weeks
assessed in both studies has beendifficult todemonstrate. The
optimum time for commencing itraconazole therapy remains
unclear; practical guidelines suggest a trial in those who have
experienced a first exacerbation on corticosteroids or those
who remain symptomatically steroid-dependent.31 Early
antifungal treatment with itraconazole has also been advo-
cated in the prevention of fibrotic lung sequelae.1,38 Experi-
ence with other antifungal agents such as voriconazole and
nebulized amphotericin B has been more limited.49,50 Despite
their widespread use, the precise role of inhaled corticoste-
roids in standard care of ABPA remains incompletely under-
stood. More recently, reports of the use of recombinant anti-
IgE antibody in ABPA have been published.51,52Aspergilloma
An aspergilloma is a localised mass of Aspergillus elements
and cellular debris which has a low potential for tissue in-
vasion due to its saprophytic nature. It most commonly
develops in a pre-existing lung cavity arising from past
tuberculosis, fibrobullous sarcoidosis, bronchiectasis,
ankylosing spondylitis or a pneumatocele and may lie
quiescent for years.43,53 Multiple aspergillomata may oc-
casionally develop and may be difficult to distinguish from
chronic cavitary aspergillosis. The most common symptom
from aspergilloma is haemoptysis which is typically mild but
has a tendency to become severe or even life-threat-
ening.54 The source of bleeding may arise from bronchial
arteries or anastomotic communications between pulmo-
nary and bronchial arteries associated with the aspergil-
loma.55 Although unusual, aspergillomas may also undergo
spontaneous shrinkage or disappear.56,57
On plain chest radiography, an aspergilloma typically ap-
pears as an ovoid or round opacity located within a lung
cavity. Localised pleural thickening may occasionally be
apparent although this sign is best appreciated on CT.58
Separation of the fungal mass from its surrounding cavity
wall may be accentuated by a crescent of air around the
mycetoma known as the Monod sign which is not to be
confused with the ‘air crescent sign’ described in invasive
aspergillosis. Positional changes of the intra-cavitary mass
during imaging may indicate its mobility within the cavity.
Occasionally, a broncho-cavitary connection may be identi-
fied (Fig. 2). Examination of sputum, bronchoalveolar lavage
(BAL) fluid and surgically resected material may reveal the
presence of Aspergillus hyphae.57 Often, elevated titres of
serum Aspergillus-specific IgG precipitins are also detected,
particularly in corticosteroid-naı¨ve patients.59
The optimal treatment for indolent or mildly symptom-
atic aspergilloma is unknown.
Systemic antifungal therapy does not effectively alter
the disease course due to poor drug penetration into
Figure 2 Sagittal CT image of a patient with solitary left
upper lobe aspergilloma and left lower lobe consolidation. A
broncho-cavitary communication is apparent (arrowhead).
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group may be more effective than amphotericin B.1 Intra-
cavitary instillation of anti-mycotics has previously been
used with variable clinical response.61,62 Although increas-
ingly available, selective embolization of bronchial and
nonbronchial arteries offers only a temporizing effect until
surgical treatment can be undertaken.63
Since the first surgical removal of aspergilloma in 1947,
experience with operative treatment has continued to grow.
Fig. 3 shows the gross pathology of a resected aspergilloma
within a lung cavity caused by sarcoidosis. It is widely
acknowledged that only surgery can offer definitive treatment
for this condition, provided that cases are appropriately
selected.64e66 Surgical complications may be substantial and
include intra-operative haemorrhage, persistent air leaks and
infection of the residual space. At times, itmay be necessary toFigure 3 Pneumonectomy specimen containing aspergilloma
in the apex of the left lower lobe. Hemorrhagic changes in the
lung parenchyma clearly demonstrated.remove a greater quantity of lung than was preoperatively
anticipated. In a retrospective analysis of 72 cases, 10-year
cumulative survival did not differ between patients undergoing
surgery and adjuvant anti-fungal therapy (74.8%) versus those
who only received surgery (78.9%).67 The optimal timing for
commencinganti-fungal agents in such setting remainsunclear.
Chronic pulmonary aspergillosis (necrotising and
cavitary)
The classification of chronic aspergillosis is complicated by
the existence of overlapping clinico-radiologic phenotypes
that may follow variable clinical courses.
Chronic necrotising pulmonary aspergillosis (CPNA),
most commonly encountered in individuals with chronic or
debilitating systemic illnesses, is one such example (Fig. 4).
Although it has the potential to cause lung tissue destruc-
tion, CPNA may remain indolent for long periods of time
without producing vascular invasion.68 The main differen-
tial diagnosis for CNPA is chronic cavitary pulmonary
aspergillosis (CCPA), a disease notable for the formation of
multiple pulmonary cavities that do not invariably contain
fungal masses.69 Such cavities may result from direct fungal
infiltration of lung parenchyma although CCPA can also
develop in existing tuberculous fibro-cavitatory spaces.69
Regardless of the specific type of chronic aspergillosis,
the ensuing lung damage may predispose to the develop-
ment of broncho-pleural fistulae.70 IgG precipitating anti-
bodies against Aspergillus antigens are positive in the
majority of affected patients and successful culture of
Aspergillus in sputum or BAL fluid, or histological confir-
mation of fungal invasion help to establish the diagnosis.
The mainstay of treatment for both these conditions is
high dose systemic antifungal therapy. In recent years, the
use of oral triazole compounds such as itraconazole and
voriconazole has overtaken the role of amphotericin B which
is now largely reserved for severe disease.71,72 However, the
optimal duration of treatment for chronic pulmonary
aspergillosis remains unclear. In one recent study of immune-Figure 4 Axial CT image illustrating features of chronic pul-
monary necrotizing aspergillosis (CPNA) including consolidative
opacities, areas of cystic change and pleural thickening (arrow-
head). Limited adjacent ground-glass attenuation is not uncom-
monly observed, denoting tissue damagewith focal haemorrhage.
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6.5 months (range 4e36 months).72 Radiological improve-
ment and fungal eradication were attained in 58% of those
who completed follow-up. Success with adjunctive admin-
istration of interferon-gamma 1b has also increased interest
in the role of ‘immune enhancers’ to boost the efficacy of
anti-fungal drugs.73,74 Surgical intervention for chronic pul-
monary aspergillosis is rarely undertaken due to the high risk
of complications and the high level of co-morbidity in
affected individuals.Figure 5 Axial CT image showing a large subpleural ‘target
lesion’ in the left lower lobe (arrow) and a smaller nodule in the
lingula in a patient with invasive pulmonary aspergillosis (IPA).
Such macronodules typically have a rim of ground-glass opacity
(the halo sign) representing haemorrhage and vascular invasion.Invasive pulmonary aspergillosis
Invasive pulmonary aspergillosis (IPA) is almost exclusively a
disease of compromised immunity such as that encountered
in transplant recipients (bone marrow and lung), those with
haematological malignancies, prolonged neutropenia, AIDS,
chronic corticosteroid treatment or cytotoxic therapy.56
Beyond these classic groups, it is increasingly appreciated
that other risk factors for IPA include anti-tumour necrosis
factor therapy, prolonged critical illness, severe COPD and
cardiothoracic and vascular surgery are increasingly
appreciated (see Table 2).75e87 In clinical series, between 5
and 10% of haematopoietic stem cell transplant (HSCT)
recipients develop IPA, mostly within the first few months
of their transplant, and face a mortality rate that exceeds
80%.88,89 For these patients, the presence of graft-versus-
host disease (GvHD), iatrogenic immunosuppression and
prolonged or severe neutropenia are major predisposing
factors to IPA.90 Overall, an underlying risk factor is not
clearly defined in around 2% of cases.91 In one review of
patients on a mixed medical-surgical ICU, risk factors for
developing IPA were categorized as high, intermediate and
low, and included determinants as diverse as severe neu-
tropenia to post-cardiac surgery status.86
Microbiologic analysis for IPA by routine methods is
challenging; up to 70% of immuno-compromised patients
with confirmed IPA may have a negative sputum culture.92
Serum and BAL fluid measurement of galactomannan
(Gm), a polysaccharide fungal cell wall component, allowsTable 2 Risk factors for developing invasive aspergillosis in the
High risk Intermediate risk
Neutropenia
(<500neutrophils/mm3)
Haematological malignancy
Allogeneic bone marrow
transplantation
Prolonged treatment with
corticosteroids before
admission to the ICU
Autologous bone marrow
transplantation
Chronic obstructive
pulmonary disease
Liver cirrhosis with a durati
of stay in the ICU 17 days
Solid-organ cancer
HIV infection
Lung transplantation
Systemic diseases requiring
immunosuppressive therapy
Adapted from Meerseman et al. 2007.86Aspergillus antigenaemia to be detected and quantified.93
The sensitivity and specificity of assaying Gm in different
at-risk populations is presently being evaluated; in the
critical care setting, the diagnostic utility of Gm in BAL fluid
has shown early promise although false positive results may
occur in patients taking beta-lactam antibiotics.78,94 Serum
assays of other Aspergillus antigens such as b-glucan are
currently in development.95
The most consistent radiologic finding in IPA is that of one
or more pulmonary macronodules typically surrounded by a
halo of ground-glass opacity, the latter representing peri-
lesional haemorrhage associated with alveolar invasion.43,44
An example is shown if Fig. 5. Depending on the stage of IPA,
other radiologic features may include the air crescent sign
(denoting infarction and retraction of the mycotic nodule)
and pneumonic consolidation. It should be noted that the
former is also encountered in other fungal infections such as
pulmonary mucormycosis.96 However, its relatively late
appearance after the acute phase of IPA limits the value ofICU categorised by likelihood of risk.
Low risk
on
Severe burns
Other solid-organ transplant recipients
(e.g., heart, kidney, or liver transplant recipients)
Steroid treatment with a duration of 7 days
Prolonged stay in the ICU (121 days)
Malnutrition
Post-cardiac surgery status
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casionally preceded by the appearance of another abnor-
mality, the hypodense sign of necrotic lung infarction.97
While the appearance of focal hypo-intensity is not limited
to IPA per se, its presence in the correct clinical setting may
strongly suggestAspergillus lung invasion.More recently, the
reverse halo sign has also been described in invasive fungal
infections although it is more commonly associated with
organising pneumonia.98 Its sensitivity for identifying IPA
remains to be tested in a larger number of cases. Pleural
effusions are unusual in IPA.99
The diagnosis of IPA can be challenging. To help weigh the
confidence of diagnosis of this and other fungal infections, a
joint group of the European Organisation for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative
Group and the National Institute of Allergy and InfectiousTable 3 Revised ETORC/MSG criteria for the diagnosis of IPA.
Criteria
Histological evidence
 Microscopic analysis of sterile material e Histopathologic,
cytopathologic or direct microscopic examination of a
specime obtained by needle aspiration or biopsy in which
hyphae or melanised yeast like forms are seen accompanied
by evidence of associated tissue damage
 Culture of sterile material e Recovery of mould or “black ye
by culture of a specimen obtained by sterile procedure form
normally sterile and clinically or radiologically abnormal site
consistent with an infectious disease process, excluding
broncho-alveolar lavage fluid, a cranial sinus cavity
specimen and urine
Host factors
 Recent history of neutropenia (<0.5  109 neutrophils/L)
for >10 days temporarily related to onset of fungal disease
 Receipt of allogenic stem cell transplant
 Prolonged use of corticosteroids (excluding patients with ABP
at a mean dose of 0.3 mg/kg/day of prednisolone for >3 we
 Treatment with either recognised T cell immunosuppressants
such as cyclosporine, TNF-a blockers, specific monoclonal
antibodies (such as laemtuzamab), or nucleoside analogues
during the past 90 days
 Inherited severe immune deficiency
(such as chronic granulomatous disease or
severe combined immunodeficiency)
Clinical criteria
 Lower respiratory tract fungal disease with the presence
on CT of one or more of (1) dense, well circumscribed lesion
with or without halo sign (2) air crescent sign (3) cavity
 Tracheobronchitis
 Sino-nasal infection
 CNS infection
Mycological Criteria
 Direct test (cytology, direct microscopy or culture)
 Indirect test
1) Galactomannan antigen in plasma, serum,
bronchoalevlar fluid or CSF) or
2) b D-glucan detected in serum
Adapted from Pauw, Walsh et al. 2008.101Diseases Mycoses Study Group (EORTC/MSG) produced
criteria (later revised) for defining the likelihood of invasive
fungal infection (Table 3).100,101 According to these criteria,
proven IPA requires the histopathologic or directmicroscopic
demonstration of Aspergillus elements in tissue from pa-
tients highly suspected as having the disease. A diagnosis of
probable IPA requires the presence of a predisposing host
factor along with clinical and mycological evidence of inva-
sive fungal disease. In this category,mycological criteria also
include indirect tests such as quantification of Gal-
actomannan in body fluids. Possible IPA cases relate to those
where appropriate host factors and clinical evidence of IPA
may be present but are not ultimately accompanied by
mycological evidence. More recently, a clinical algorithm
based on satisfying 4 criteria incorporating Aspergillus cul-
ture from the respiratory tract, compatible clinical findings,Proven Probable Possible
Required Absent/
not available
Absent/
not available
ast”
Not required Required Required
A)
eks
,
Not required Required Required
(s)
Not required Required Absent
1120 G. Tunnicliffe et al.suggestive radiological abnormalities and a host predisposing
factor (such as neutropenia).87
IPA is associated with a very high mortality even when
empiric treatment is initiated early.102 Treatment failure is
common when it is administered late or to patients who are
profoundly neutropenic or have disseminated disease.91,94
Of the triazole-based agents, voriconazole is widely rec-
ommended as first line treatment for IPA due to its superior
efficacy over amphotericin B and its additional actions
against Aspergillus terreus.1,103e105 There is increasing ev-
idence that therapeutic drug monitoring (TDM) of vor-
iconazole may improve treatment endpoints. Unwanted
and at times severe adverse effects as well as treatment
inefficacy occur as a result of unpredictable variations in
circulating voriconazole levels. In one study of over 50 adult
patients on this drug, voriconzole TDM improved both
treatment success and safety.106 In a more recent ran-
domized study of 110 patients with invasive fungal in-
fections, patients assigned TDM were found to develop
fewer adverse drug events and experience a higher rate of
partial or complete treatment response.107 However, the
usefulness of TDM of voriconazole has failed to be shown in
other studies. Plasma trough concentrations were found to
correlate poorly with drug dose and treatment response in
immunocompromised pediatric patients with invasive
fungal disease.22 In the adult population, a large retro-
spective multi-center study that evaluated 264 patients
receiving voriconazole as targeted or pre-emptive treat-
ment of IPA failed to find a correlation between its con-
centration and treatment outcome.108
Combination therapy with different anti-fungals is used
when disease progression occurs on single-agent treatment.
However, the potential for adverse drug interactions with
poly-pharmacy should borne in mind and the role of com-
bination antifungal therapy in aspergillosis as either initial
or salvage therapy remains unproven. Combination therapy
is not recommended in current practice guidelines. Pos-
aconazole and caspofungin have been shown to be effective
in refractory cases of invasive aspergillosis.109,110 In addi-
tion, Caspofungin has been shown to be efficacious as
salvage therapy in patients intolerant of or resistant to
standard anti-fungal treatment.1 A randomised trial
comparing voriconazole with or without anidulafungin is
currently underway.111 In individuals at high risk of IPA, a
role for prophylactic posaconazole has been suggested (1).
Encouraging results with immune augmentation strategies
using myeloid colony stimulating factors (G-CSF or GMCSF)
and recombinant interferon-gamma (IFN experience in this
field remains relatively limited.1,112,113 A successful
outcome following surgical intervention of IPA has also been
previously reported but this approach, for obvious reasons,
is unsuitable for most patients.114,115
Summary
The apparent frequency of pulmonary aspergillosis has risen
as a result of greater clinical awareness, improved detection
and perhaps most significantly, an increasing number of at-
risk individuals. Susceptibility to aspergillosis is not confined
to those with classical risk factors such as neutropenia and
allogeneic organ transplant. It is increasingly recognized
that susceptible patients also include those requiring organsupport on critical care units, those affected by malig-
nancies, chronic debilitating conditions, granulomatous lung
disorders and iatrogenic immunosuppression related to the
use of anti-biologic agents. The development of new diag-
nostic laboratory tests is expected to meet demands for
increasingly sophisticated ways to prove Aspergillus patho-
genicity. More accurate radiological characterization of
fungus-associated airway and lung damage will broaden the
role of CT as a crucial diagnostic tool. Although medical
treatment of pulmonary aspergillosis as a whole remains
challenging, an increasing number of pharmacological
agents are now available to the treating clinician. In recent
years, realization that susceptibility to specific forms of this
disease is inherently influenced by a dysfunctional host
defence system has led to the use of immune-modulatory
strategies such as anti-IgE antibodies (for ABPA) and re-
combinant interferon-gamma therapy (for chronic necro-
tizing and invasive aspergillosis). Much hope has also been
placed on the application of functional genomics to identify
Aspergillus targets againstwhich antifungal agentswill exert
greater activity. Failure to control the clinical burden
wrought by Aspergillus fungi will inevitably mean a dispro-
portionately higher death toll amongst relatively select
groups of vulnerable individuals.Conflict of interest statement
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